Zealand Pharma (ZLDPF) announced that the last participant has been enrolled and randomized to active treatment or placebo in ZUPREME-1, a global Phase 2b trial in people with obesity or ...

Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Ascendis Pharma (ASND – Research Report) today and set a price target of $180.00. The company’s shares closed last Friday at ...

Purdue Pharma filed a new bankruptcy plan on Tuesday, a major step toward finalizing a proposed opioid settlement of at least $7.4 billion after a setback in the U.S. Supreme Court last year.

Mar. 18, 2025 — A research team has found that lecanemab was probably less effective in females than males in its Phase 3 trial. However, there was insufficient evidence to say the drug was ...

For years, Jeff Simmons — the president and CEO of the large US pharmaceutical company Elanco — ridiculed a seemingly unlikely target on social media: the plant-based meat industry.

Opinions expressed are those of the author. 2025 is going to be a big year for AI adoption in pharma. By now, most life science companies have at least experimented with one generative AI (GenAI ...

Blog posts represent the views of CFR fellows and staff and not those of CFR, which takes no institutional positions. Most of the major U.S. pharmaceutical companies (AbbVie, Amgen, Bristol Myers ...

Wall Street expects a year-over-year increase in earnings on lower revenues when Verrica Pharmaceuticals Inc. (VRCA) reports results for the quarter ended December 2024. While this widely-known ...

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.40 per share a year ago.

With a powerful logo and striking color, the brand captures and amplifies the spirit and energy of the WTA, bringing the drama of women's tennis to life like never before. Honoring the WTA's ...

However, I think aggressive growth investors might want to consider buying Madrigal Pharmaceuticals' shares. Some analysts project that Rezdiffra could generate peak annual sales of close to $3.5 ...

Recursion Pharmaceuticals showcased significant progress in advancing its pipeline and platform capabilities, supported by clinical data readouts and partnerships with Roche and Sanofi.